For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy1
JUST 2 DOSES A YEAR* ADMINISTERED BY AN HCP. NO SELF-INJECTIONS.
NO INFUSIONS.1
2 INITIAL DOSES, THEN 2 DOSES A YEAR1
*After 2 initial doses and taken with statin therapy.1
†Always check the expiration date on the prefilled syringe before administration.
No dose adjustments
No refrigeration1
Single-dose prefilled syringe1
Shelf life of 3 years2†
No required post-injection–related safety monitoring
Remember: Do not remove the needle cap until you are ready to inject.
For detailed instruction on administration, see Instructions for Use.
Dosing regimen may integrate seamlessly into a patient’s health care routine.
SUBCUTANEOUS INJECTION BY ANY STATE-CERTIFIED HCP1
Remember: Do not remove the needle cap until you are ready to inject.
For detailed instruction on administration, see Instructions for Use.
Not actual size.
27 gauge, 1/2-inch needle.3
ONCE ADMINISTERED, NO CHANCE OF A MISSED DOSE FOR 6 MONTHS1*
Alirocumab is dosed every 2 weeks (75 mg-150 mg), equating to 26 injections/year. The monthly dose of PCSK9 mAbs is administered by giving 2 or 3 injections consecutively, which equates to 24 to 36 injections/year.5
This is not a complete list of all the available treatments to patients with primary hyperlipidemia. The comparison pertains only to difference in dosing and administration and should not be considered a comparison of efficacy or safety.
*After two initial doses and taken with statin therapy.1
Additional dosing information1
LEQVIO is administered into the abdomen, upper arm, or thigh
If a planned dose is missed by less than 3 months, administer LEQVIO and maintain dosing according to the patient's original schedule
If a planned dose is missed by more than 3 months, start a new dosing schedule—administer initially, again at 3 months, and then every 6 months
In-office administration1
In-office administration of LEQVIO adds minimal burden to your patients' existing medication and care regimen
Reduces LDL-C without adding an additional daily treatment
No specific label requirement for post-injection–related safety monitoring
Remember: Do not remove the needle cap until you are ready to inject
For detailed instruction on administration, see Instructions for Use.
SEE WHAT YOU NEED TO KNOW ABOUT LEQVIO (inclisiran) DOSING
Get the facts on all aspects of LEQVIO administration, including details on how to inject LEQVIO, key product information, and finding the right person in your practice to administer.
THERE’S MORE TO KNOW ABOUT LEQVIO
Explore the LEQVIO mechanism of action
LDL-C, low-density lipoprotein cholesterol.